Home
Geneva, 2 February 2010
As BioSquare 2010 winds down this evening I am filled with gratitude towards all the sponsors, partners and participants who made this our most successful BioSquare ever. Deals were made, contacts were countless and the venue was extremely well received. As you can imagine, we are not stopping here. BioSquare 2011 will dare go further which is why we invite you to visit our website in early March for some outstanding news. Finally, I would also like to thank our staff and service partners who gave me incredible support.
In closing, I wish you continued business development throughout 2010.
Warm regards,
Bernadette Guagliata, CEO
Redefining Healthcare through Bioconvergence
"The dizzing pace of innovation promises to redefine healthcare. The combination of biotechnology with nanotechnology, medtechnology and information technology will transform the way doctors monitor, diagnose and treat disease.
BioSquare is totally part of this deep and global transformation of the sector: the conference is a two-day event which aims at bringing together stakeholders from across the value chain of these innovative technologies convergence. BioSquare 2010 will concentrate time and expertise for theses companies looking for partnerships in one of the world’s key financial place.”
G. Steven Burrill, CEO Burrill & Company
Patrick Aebischer, G. Steven Burrill, Pierre Hessler, Elmar Schnee, Paul Stoffels and Christopher A. Viehbacher to deliver Opening Keynote address
BioSquare Keynote Event: Monday February 1st, 2010 at 11:15 am
 |
 |
 |
| Patrick Aebischer President, Ecole Polytechnique de Lausanne | G. Steven Burrill, CEO, Burrill & Company | Pierre Hessler Member of the Directoire, Capgemini Service SAS |
 |
 |
 |
| Elmar Schnee, President, Merck Serono | Paul Stoffels, Global Head, R&D, Pharmaceuticals Johnson & Johnson | Christopher A. Viehbacher, CEO, Sanofi-aventis |
BioSquare V2.0
Fact
Effective partnering opportunities lead to successful ventures.
Fact
Biotech, medtech, nanotech and in silico sectors are coming together as never before; we are witnessing the birth of bioconvergence.
Fact
The new BioSquare is the premiere bioconvergence partnering meeting for mature companies, high potential start-ups or willing investors working in the bioconvergence universe worldwide.
Fact
Expect an event that adds to your bottom line.
Did we mention it’s going to be the most enjoyable BioSquare ever?
BioSquare V2.0 Highlights
BioSquare has set high goals. It has also retained key fundamentals.
 | Make valuable business connectionsThe one-to-one paradigm lives on but with major changes. You will meet people in far more comfort, with greater privacy and with superior presentation options. |
Who should attend?
BioSquare targets decision-makers that are ready to deal.
Historically, 46% of BioSquare attendees are President/CEO/Partner level, 21% are Senior VP/Director level and the remainder is academia, media and middle management. Over the last three BioSquare events the trend has been leaning towards higher-level attendees (President/CEO/Partner).
Sectorially, those that have regularly attended BioSquare are bio-technology companies, medical-technology companies, nano-technology companies, diagnostics, pharmaceutical, technology licensing offices, major research institutions, high potential start-ups and investment companies and individuals — without planning on it, we were a bioconvergence event all along.
Clearly, all life sciences players are welcome, but our focus is on companies that are sufficiently mature in their development to warrant an imminent investment or partnership.